The case for infectious endocarditis prophylaxis: Time to move forward

Archives of Internal Medicine

Volumn 167, Issue 4, 2007, Pages

  Seto, Todd B ^a,b   Morris, Andrew Mark ^c  

^a UNIVERSITY OF HAWAII   (United States)

^b QUEEN S MEDICAL CENTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; SIMVASTATIN;

ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; BACTERIAL ENDOCARDITIS; COST EFFECTIVENESS ANALYSIS; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MITRAL VALVE PROLAPSE; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DENTAL CARIES; ENDOCARDITIS, BACTERIAL; HUMANS; MORBIDITY; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 33847365747     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.4.327     Document Type: Review

References (0)